



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CGP35348

Cat. No.:	HY-103530		
CAS No.:	123690-79-9		
Molecular Formula:	C ₈ H ₂₀ NO ₄ P		
Molecular Weight:	225.22		
Target:	GABA Receptor		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 83.33 mg/mL (369.99 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	4.4401 mL	22.2005 mL	44.4010 mL	
		5 mM	0.8880 mL	4.4401 mL	8.8802 mL	
		10 mM	0.4440 mL	2.2201 mL	4.4401 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS					
	Solubility: 25 mg/mL (111.00 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	CGP 35348 is a selective, brain penetrant, centrally active GABAB receptor antagonist with an EC ₅₀ of 34 μM. CGP 35348 shows affinity for the GABAB receptor only ^[1] . CGP 35348 has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage ^[2] .		
In Vivo	CGP 35348 enhances non-REM sleep and rapid eye movement (REM) sleep and reduces strongly spike-wave discharges ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Eight male Wistar rats ^[3]	
	Dosage:	100, 300, and 900 mg/kg	
	Administration:	Intraperitoneally given	

Result:	Produced an increase in the duration of REM sleep compared to the saline-injected control group at 100 and 300 mg/kg.
---------	---

REFERENCES

[1]. H R Olpe, et al. CGP 35348: a centrally active blocker of GABAB receptors. CGP 35348: a centrally active blocker of GABAB receptors

[2]. Q Gillani, et al. CGP 35348, GABA B receptor antagonist, has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage. Biomed Res Int. 2014;2014:295215.

[3]. A Puigcerver, et al. Effects of the GABAB antagonist CGP 35348 on sleep-wake states, behaviour, and spike-wave discharges in old rats. Brain Res Bull. 1996;40(3):157-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA